Human Psychopharmacology: Clinical and Experimental This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products
ConclusionsBeing sold as a legal product, Psyclone may appeal to recreational users, who remain unaware of its real content. This is a serious public health threat, which may lead to acute intoxications and fatalities. Further studies in the field, including Internet monitoring, are therefore required. Copyright © 2015 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - July 28, 2015 Category: Psychiatry Authors: Rita Santacroce, Ornella Corazza, Giovanni Martinotti, Francesco Saverio Bersani, Giuseppe Valeriani, Massimo Di Giannantonio Tags: Special Issue on Novel Psychoactive Substances Source Type: research

Injecting eye‐drops: a mini‐review on the non‐clinical use of tropicamide
ConclusionsTropicamide IV injections represent a serious health risk. Specific prevention programmes should be implemented for the general population as well as for the high‐risk population of polydrug abusers. Copyright © 2015 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - July 28, 2015 Category: Psychiatry Authors: Francesco Saverio Bersani, Claudio Imperatori, Mariya Prilutskaya, Ramiz Kuliev, Ornella Corazza Tags: Special Issue on Novel Psychoactive Substances Source Type: research

Venlafaxine as the ‘baby ecstasy’? Literature overview and analysis of web‐based misusers′ experiences
ConclusionsPhysicians should carefully evaluate patients for history of drug dependence and observe them for signs of venlafaxine misuse. Copyright © 2015 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - July 28, 2015 Category: Psychiatry Authors: Giulia Francesconi, Laura Orsolini, Duccio Papanti, John M. Corkery, Fabrizio Schifano Tags: Special Issue on Novel Psychoactive Substances Source Type: research

Olanzapine as the ideal “trip terminator”? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance‐related psychotic symptoms
ConclusionsOnly a few research studies have formally assessed the effectiveness of olanzapine and indeed of other second‐generation antipsychotics to treat NPS‐induced psychosis. Olanzapine was suggested here from a range of pro drug websites as being the “ideal” molecule to terminate “bad trips”. Health professionals should be informed about the risks related to olanzapine misuse. Copyright © 2015 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - July 28, 2015 Category: Psychiatry Authors: Giuseppe Valeriani, Ornella Corazza, Francesco Saverio Bersani, Claudia Melcore, Antonio Metastasio, Giuseppe Bersani, Fabrizio Schifano Tags: Special Issue on Novel Psychoactive Substances Source Type: research

Methoxetamine‐related deaths in the UK: an overview
ConclusionsMore research needs to be conducted into its health effects and toxicity potential. Health care professionals should be made aware of the potential health harms of MXE, in order to develop early intervention measures and minimise the number of MXE‐related poisonings and fatalities. Copyright © 2015 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - July 28, 2015 Category: Psychiatry Authors: Stefania Chiappini, Hugh Claridge, John M. Corkery, Christine Goodair, Barbara Loi, Fabrizio Schifano Tags: Special Issue on Novel Psychoactive Substances Source Type: research

Is there any difference in patterns of use and psychiatric symptom status between injectors and non‐injectors of mephedrone?
ConclusionsIntravenous mephedrone use is associated with a higher risk of harmful drug use, elevated psychiatric symptom profile and increased possibility of mephedrone being considered as an addictive substance. These findings might be important in efficient treatment planning. Copyright © 2015 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - July 28, 2015 Category: Psychiatry Authors: Máté Kapitány‐Fövény, Barbara Mervó, Máté Kertész, Ornella Corazza, Judit Farkas, Gyöngyi Kökönyei, Róbert Urbán, Zsolt Demetrovics Tags: Special Issue on Novel Psychoactive Substances Source Type: research

Deaths of individuals aged 16–24 years in the UK after using mephedrone
ConclusionsMephedrone use can have potentially fatal consequences, especially in combination with other substances. Deaths from its use in the 16–24 years' age group continue to occur in the UK, despite it being a controlled drug. Health professionals and potential consumers should be alert to this risk. Copyright © 2015 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - July 28, 2015 Category: Psychiatry Authors: Barbara Loi, John Martin Corkery, Hugh Claridge, Christine Goodair, Stefania Chiappini, Carla Gimeno Clemente, Fabrizio Schifano Tags: Special Issue on Novel Psychoactive Substances Source Type: research

Why all stimulant drugs are damaging to recreational users: an empirical overview and psychobiological explanation
ConclusionsRepetitive CNS stimulation is potentially damaging to the organism, both acutely and chronically. The review describes the various psychobiological systems through which recreational stimulant drugs impair human well‐being. Copyright © 2015 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - July 28, 2015 Category: Psychiatry Authors: Andrew C. Parrott Tags: Special Issue on Novel Psychoactive Substances Source Type: research

Novel psychoactive substances: second and third international conferences
(Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - July 28, 2015 Category: Psychiatry Tags: Editorial Source Type: research

Issue Information
No abstract is available for this article. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - July 28, 2015 Category: Psychiatry Tags: Issue Information Source Type: research

Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors
ConclusionsTreatment with SSRIs and duloxetine improved functional impairment in patients with major depressive disorder. Higher SDS or 17‐item Hamilton Depression Rating Scale baseline scores predicted less probability of SDS improvement; female gender predicted better improvement in functional impairment at endpoint. © 2015 The Authors. Human Psychopharmacology: Clinical and Experimental published by John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - July 1, 2015 Category: Psychiatry Authors: David V. Sheehan, Michele Mancini, Jianing Wang, Lovisa Berggren, Haijun Cao, Héctor José Dueñas, Li Yue Tags: Research Article Source Type: research

Aripiprazole for Tourette's syndrome: a systematic review and meta‐analysis
ConclusionThis review found that ARI has similar efficacy to TIA and HAL for TS, while extrapyramidal symptoms were significantly less with ARI than with HAL. ARI can be considered as an alternative treatment option for TS. Copyright © 2015 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - July 1, 2015 Category: Psychiatry Authors: Wei Zheng, Xian‐Bin Li, Ying‐Qiang Xiang, Bao‐Liang Zhong, Helen F. K. Chiu, Gabor S. Ungvari, Chee H. Ng, Grace K. I. Lok, Yu‐Tao Xiang Tags: Research Article Source Type: research

Serial pharmacological prescribing practices for tic management in Tourette syndrome
We present this heterogeneous cohort in terms of the number of drugs they had tried, and as a proxy measure of some benefit of the last drug used, whether it had been prescribed under our supervision for ≥5 months. The most commonly prescribed medications were aripiprazole (64%), clonidine (40%), risperidone (30%) and sulpiride (29%) with changes in prescribing practises over the period examined. The number of different drugs tried were one (n = 155), two (n = 69), three (n = 36), four (n = 14), five (n = 15), six (n = 5), seven (n = 2) and eight (n = 1). The data illustrate the difficul...
Source: Human Psychopharmacology: Clinical and Experimental - July 1, 2015 Category: Psychiatry Authors: Mena Farag, Jeremy S. Stern, Helen Simmons, Mary M. Robertson Tags: Research Article Source Type: research

Can cognitive behaviour therapy beneficially influence arousal mechanisms in psychosis?
Cognitive behavioural therapy for psychosis (CBTp) is an approved adjunct therapy for patients with psychotic disorders; however, we do not fully understand the neurobiological effects that this therapy may exert. Arousal, as measured by electroencephalography (EEG), provides a useful electrophysiological marker for assessing psychotic disorders. EEG studies may therefore serve as a useful measure for assessing the underlying effects of CBTp in psychotic disorders. Copyright © 2015 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - July 1, 2015 Category: Psychiatry Authors: Fleur M. Howells, David S. Baldwin, David G. Kingdon Tags: Short Communication Source Type: research

Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder
Around half the inmates in prison institutions have antisocial personality disorder (ASPD). A recent theory has proposed that a dysfunction of the endogenous opioid system (EOS) underlies the neurobiology of borderline personality disorder (BPD). In the present theoretical paper, based on a comprehensive database and hand search of the relevant literature, this hypothesis is extended to ASPD, which may be the predominant expression of EOS dysfunction in men, while the same pathology underlies BPD in women. According to evidence from human and animal studies, the problematic behaviours of persons with antisocial, callous, o...
Source: Human Psychopharmacology: Clinical and Experimental - July 1, 2015 Category: Psychiatry Authors: Borwin Bandelow, Dirk Wedekind Tags: Review Article Source Type: research